GLYC

GlycoMimetics, Inc.

0.26 USD
+0.01 (+2.92%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

GlycoMimetics, Inc. stock is down -1.93% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 PUTs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Apr 18:27 21 Jun, 2024 2.50 PUT 647 2665
01 May 18:02 21 Jun, 2024 4.00 PUT 150 6663
06 May 13:35 17 May, 2024 2.50 PUT 150 11500
06 May 14:09 21 Jun, 2024 2.50 PUT 500 3567
06 May 14:14 21 Jun, 2024 2.50 PUT 140 3567
06 May 14:16 20 Sep, 2024 2.50 PUT 150 3001
06 May 14:19 17 May, 2024 2.50 PUT 3741 11500
06 May 14:21 21 Jun, 2024 2.50 PUT 1496 3567
06 May 14:26 17 May, 2024 2.50 PUT 2245 11500
06 May 14:32 17 May, 2024 2.50 PUT 1496 11500

About GlycoMimetics, Inc.

GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.